Veradermics, a New Haven-based biotech firm developing hair loss treatments, saw its shares surge over 100% in its New York Stock Exchange debut on Tuesday. The company’s upsized initial public offering priced at $17 per share, raising significant capital as it advances a potential first-of-its-kind non-hormonal oral therapeutic for hair regrowth.
The stock reached $37.85 in early trading, representing a massive jump from its initial pricing. Veradermics successfully expanded its offering to 15.1 million shares, up from an original target of 13.35 million. This high demand pushed the final price to $17, surpassing the previously anticipated range of $14 to $16 per share.
Institutional interest played a central role in the offering's momentum. According to a Monday prospectus, pharmaceutical giant Eli Lilly expressed interest in acquiring up to a 4.9% stake at the IPO price. The company also maintains a strong roster of existing backers, including Longitude Capital, which held a 17.9% pre-IPO stake, alongside SR One and Suvretta Capital.
Advancement of the Lead Candidate
The market enthusiasm centers on VDPHL01, a drug Veradermics claims could become the first non-hormonal oral treatment for hair regrowth in both men and women. The company reached a critical milestone in December, completing enrollment for a Phase 2/3 clinical trial specifically targeting male pattern hair loss.
Veradermics is currently supported by a group of prominent venture and investment firms, including:
- Longitude Capital
- SR One
- J.W. Childs Associates
- Suvretta Capital
Comments (0)
No comments yet. Be the first!